Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData.
The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases...
Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook...
Shire has announced that James Bowling, Interim Chief Financial Officer, has notified the Board...
AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee. The two companies said the deal was off following the decision last week by AbbVie's board to withdraw support from the proposed acquisition.
AbbVie's board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.
Shire wants AbbVie to stick with its roughly $55 billion acquisition bid, and it is reminding its U.S. counterpart of the hefty breakup fee it will receive if things don't work out.
Shire and ArmaGen announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).
The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire.
AbbVie and Shire are in detailed talks about a possible combination after AbbVie once again raised the deal price and gave Shire shareholders a bigger stake in the new company. Shire says North Chicago, Illinois-based AbbVie is now offering a cash-stock combination valued at 53.20 British pounds ($91.10) for each share of Shire, which is headquartered on the British island of Jersey.
U.S. drugmaker AbbVie says it sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.
Shire highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie.
Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Use of Vyvanse in Preschool-Age ChildrenJune 12, 2014 9:13 am | News | Comments
Shire announced that it has agreed to a written request by the Food and Drug Administration (FDA) to conduct pediatric clinical studies to investigate the potential use of Vyvanse (lisdexamfetamine dimesylate) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in preschool-age children, ages 4 to 5.
Following a May 15, 2014, meeting with the FDA, Shire intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter of 2015. In parallel to preparing for the NDA submission, Shire will be assessing the need for gathering additional clinical data in support of the U.S. and potential international regulatory submissions.
Shire has announced the acquisition of Lumena Pharmaceuticals, Inc., a biopharmaceutical company with rare disease pipeline assets.
Shire is recalling one batch of its Gaucher disease treatment Vpriv because particulate matter was discovered in some vials of the drug.
Shire has announced that the FDA has approved the production of VPRIV drug substance (velaglucerase alfa for injection) in Shire's manufacturing facility in Lexington, Massachusetts. The facility was previously approved by the European Medicines Agency (EMA) for production of VPRIV drug substance.
Shire has announced top-line results from two pivotal Phase 3 investigational studies evaluating the efficacy and safety of Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) versus placebo as an adjunctive treatment for major depressive disorder (MDD) in adults who inadequately responded to antidepressant monotherapy with a SSRI or SNRI.
Shire PLC has successfully completed its $4.2 billion tender offer for the rare disease treatment developer ViroPharma Inc. and said Friday it hopes to quickly complete the deal.
Shire plc today announces that Matthew Emmens will retire as Non-Executive Chairman and Susan Kilsby, Chairman of Shire's Audit, Compliance & Risk Committee will succeed him after the conclusion of Shire's AGM on 29 April 2014.
The Irish drugmaker booked no upfront payment with the sale of the treatment, Dermagraft, but it said Friday it could receive up to $300 million in cash if Organogenesis meets certain sales targets between now and 2018.
Shire says it is buying the rare disease biopharmaceutical company ViroPharma in a deal worth $4.2 billion. ViroPharma makes CINRYZE, which treats hereditary angioedema, a disease characterized by recurrent attacks of swelling of the skin or mucous membranes.
Biopharmaceutical company Questcor Pharmaceuticals Inc. said Monday that the recently retired CEO of Shire PLC, Angus C. Russell, has been added to its board. Russell was CEO of Shire, also a biopharmaceutical company, for five years. Before that, he was an executive at pharma companies ICI, Zeneca and AstraZeneca.
Shire LLC said Friday that it has settled its patent dispute with Teva Pharmaceuticals USA Inc. over Teva's efforts to sell a generic version of its drug used for treatment of attention deficit hyperactivity disorder.The settlement allows Teva to market a generic version of Shire's Intuniv extended release tablets or generic versions supplied by Shire.
Irish drugmaker Shire PLC said Thursday its net income fell in the first quarter, and it lowered its revenue forecast because sales of several of its drugs are under pressure. Sales of its ADHD drug Adderall XR have been sliding because of growing generic competition. They fell 10 percent to $99.8 million during the quarter.
Shire plc, announces that it has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially blinding eye disorder that primarily affects premature infants and is one of the most common causes of visual loss in childhood.
Shares of Shire PLC sank Thursday morning after the Irish drugmaker said its fourth-quarter earnings tumbled 84 percent on climbing costs and generic competition for its attention deficit hyperactivity disorder drug. The Dublin company earned $42 million, or 22 cents per share, in the three months that ended Dec. 31.
Teva Pharmaceutical Industries Ltd. said Thursday that it received marketing approval for a generic version of Shire PLC's Adderall XR, a treatment for attention deficit hyperactivity disorder. The Food and Drug Administration approved Teva's generic in six strengths from 5 milligrams to 30 milligrams.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. (collectively Shire) relating to supply of its authorized generic Adderall XR® under the parties’ License and Distribution Agreement that was signed in January 2006. As part of the settlement, the parties will submit a stipulation of dismissal for entry by the Court.
- Page 1